#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

### Schedule 14A

#### Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

 Filed by the Registrant
 ⊠

 Filed by a party other than the Registrant
 □

#### Check the appropriate box:

Preliminary Proxy Statement

□ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

□ Definitive Proxy Statement

Definitive Additional Materials

□ Soliciting Material under §240.14a-12

# **Relmada Therapeutics, Inc.**

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

## Payment of Filing Fee (Check all boxes that apply):

No fee required

□ Fee paid previously with preliminary materials.

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11



## **RELMADA THERAPEUTICS, INC.**

2024 Annual Meeting Vote by May 23, 2024 11:59 PM ET



V45101-P05203

# You invested in RELMADA THERAPEUTICS, INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the stockholder meeting to be held on May 24, 2024.

# Get informed before you vote

Relmada

RELMADA THERAPEUTICS, INC. 2222 PONCE DE LEON BLVD., 3<sup>40</sup> FLOOR CORAL GABLES, FLORIDA 33134

View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 10, 2024. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



\*Please check the meeting materials for any special requirements for meeting attendance.

# THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters.

Voting Items		Board Recommends
1.	To elect Class III directors, to serve for a three-year term that expires at the Annual Meeting of Stockholders in 2027, or until his successor is elected and qualified or until his earlier resignation or removal.	
	Nominees:	Ser For
	01) John Glasspool 02) Paul Kelly	
2.	To ratify the appointment of Marcum LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.	Ser For
3.	To approve an amendment to the Relmada Therapeutics, Inc. 2021 Equity Incentive Plan to increase the shares of our common stock available for issuance thereunder by 4.5 million shares.	Ser For
4.	To provide an advisory vote to approve executive compensation.	Ser For
<b>NOTE:</b> To consider and act upon any other business as may properly come before the Annual Meeting or any adjournments thereof.		

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings".

V45102-P05203